{
  "run_id": "17c17e85-d13b-44f0-836a-169b2d148fa5",
  "prompt_variant_id": "22a9af00-9f14-4d43-9f64-19c6b3b6379d",
  "api_config_name": "model_gpt_3_5_turbo",
  "test_case_id": "breast_cancer_her2_positive",
  "start_time": "2025-09-01T14:39:02.058335",
  "end_time": "2025-09-01T14:39:03.930646",
  "duration_ms": 1869.0388202667236,
  "success": true,
  "error_message": "",
  "entities_extracted": 16,
  "entities_mapped": 14,
  "extraction_completeness": 1.0,
  "mapping_accuracy": 0.45454545454545453,
  "precision": 0.8235294117647058,
  "recall": 0.875,
  "f1_score": 0.8484848484848485,
  "compliance_score": 1.0,
  "token_usage": 3485,
  "extracted_entities": [
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 0.9,
      "source_context": {
        "section": "Conditions",
        "position": 11,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 0.9,
      "source_context": {
        "section": "Conditions",
        "position": 39,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 33,
        "context_sentence": "Histologically confirmed HER2-positive metastatic breast cancer",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Measurable disease per RECIST 1.1",
      "type": "condition",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 64,
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "ECOG performance status 0-1",
      "type": "demographic",
      "attributes": {},
      "confidence": 0.7,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 89,
        "context_sentence": "ECOG performance status 0-1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Adequate organ function",
      "type": "condition",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 111,
        "context_sentence": "Adequate organ function",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Prior treatment with Trastuzumab Deruxtecan",
      "type": "exclusion",
      "attributes": {},
      "confidence": 0.9,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": 13,
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Active brain metastases",
      "type": "condition",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": 39,
        "context_sentence": "Active brain metastases",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Pregnancy or breastfeeding",
      "type": "condition",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": 61,
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "novel HER2-targeted therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": "novel",
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": 19,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "temporal_context": "current"
      },
      "confidence": 0.8,
      "source_context": {
        "section": "briefSummary",
        "position": 53,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "progressed on prior trastuzumab-based therapy",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "temporal_context": "past"
      },
      "confidence": 0.7,
      "source_context": {
        "section": "briefSummary",
        "position": 99,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefTitle",
        "position": 23,
        "context_sentence": "Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Phase III Study",
      "type": "procedure",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "officialTitle",
        "position": 2,
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Novel Targeted Therapy",
      "type": "medication",
      "attributes": {},
      "confidence": 0.85,
      "source_context": {
        "section": "officialTitle",
        "position": 12,
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "officialTitle",
        "position": 39,
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    }
  ],
  "mcode_mappings": [
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Breast Cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 0",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "06cbde81-a226-4eed-87db-7f76d44c09ef",
      "llm_source_text_fragment": "Entity index 0",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic Breast Cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 1",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "f3a9c153-5dc0-4ddf-832b-edb84c9036f5",
      "llm_source_text_fragment": "Entity index 1",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 2",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "1334242c-e2ea-4c4c-a9c6-e83266f8651d",
      "llm_source_text_fragment": "Entity index 2",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Measurable disease per RECIST 1.1",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 3",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "9f4daa6e-e509-4fc2-9a18-669b3a1fcd13",
      "llm_source_text_fragment": "Entity index 3",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "ECOGPerformanceStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "ecogperformancestatus",
        "display": "ECOGPerformanceStatus"
      },
      "value": "0-1",
      "mapping_confidence": 0.7,
      "source_text_fragment": "Entity index 4",
      "mapping_rationale": "Mapped to ECOGPerformanceStatus based on the text and confidence level",
      "id": "cdfd2f63-26cb-49a5-9f0c-2b8fe3cd4ae5",
      "llm_source_text_fragment": "Entity index 4",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab Deruxtecan",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 6",
      "mapping_rationale": "Mapped to CancerRelatedMedication based on the text and confidence level",
      "id": "3793bfaf-5217-4620-acbb-d072b1fadb86",
      "llm_source_text_fragment": "Entity index 6",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Active brain metastases",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 8",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "12f7d4d7-449e-473a-b6a2-dda8a49cec57",
      "llm_source_text_fragment": "Entity index 8",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Pregnancy or breastfeeding",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 9",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "0bcde3aa-b8ce-412d-878c-50764dee2608",
      "llm_source_text_fragment": "Entity index 9",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "novel HER2-targeted therapy",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 10",
      "mapping_rationale": "Mapped to CancerRelatedMedication based on the text and confidence level",
      "id": "2edc896c-d51d-486e-96ab-8c5d57e111cf",
      "llm_source_text_fragment": "Entity index 10",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 11",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "73f8db2c-7917-4c9b-8060-ecf46c265101",
      "llm_source_text_fragment": "Entity index 11",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "progressed on prior trastuzumab-based therapy",
      "mapping_confidence": 0.7,
      "source_text_fragment": "Entity index 12",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "e4b50195-cb92-4009-b564-e7aaa3fe76ee",
      "llm_source_text_fragment": "Entity index 12",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Breast Cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 13",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "b2c22e50-852f-4784-b51c-9c9b0a849847",
      "llm_source_text_fragment": "Entity index 13",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "Novel Targeted Therapy",
      "mapping_confidence": 0.85,
      "source_text_fragment": "Entity index 14",
      "mapping_rationale": "Mapped to GenomicVariant based on the text and confidence level",
      "id": "a61c4529-f734-4f17-a19f-7142b54db563",
      "llm_source_text_fragment": "Entity index 14",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Metastatic Breast Cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 15",
      "mapping_rationale": "Mapped to CancerCondition based on the text and confidence level",
      "id": "879829d3-0c49-487c-9ae3-7b560913be15",
      "llm_source_text_fragment": "Entity index 15",
      "source_references": []
    }
  ],
  "validation_results": {
    "valid": true,
    "errors": [],
    "warnings": [],
    "compliance_score": 1.0
  }
}